Alembic Pharmaceuticals acquires Utility Therapeutics for $12 million to strengthen US footprint

The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market

SeQuent–Viyash merger receives stock exchange approvals; NCLT filing underway

Kerala Ayurveda reports FY25 consolidated revenue higher by 22% at Rs. 137.2 Cr

Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year

Merck KGaA, Darmstadt, Germany, Showcases Innovation at ASCO 2025

Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025

Marksans Pharma FY25 PAT up 21% at Rs. 382.6 Cr

Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24

Zydus Wellness records a growth of 30% in net profit in FY25

EBITDA for the period rose by 23.2% to Rs. 3,797 million

Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr

The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore

Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr

PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%

Sanofi Consumer Healthcare India Q1 PAT up 12.9%

The Q1 2025 also witnessed a successful launch of Allegra D

Gandhar Oil Refinery (India) Q3 FY25 consolidated revenues reaches Rs. 1,005.3 Cr

Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL